Eris Lifesciences and Natco Pharma Join the Race for India’s Semaglutide Market
Ahmedabad-based Eris Lifesciences has partnered with Natco Pharma to commercialize semaglutide in India, capitalizing on the anticipated patent expiry in March and the surging demand for weight-loss drugs. This collaboration leverages Eris’s strong commercial presence in the diabetes segment and Natco’s expertise in manufacturing and regulatory affairs for complex formulations.
The Semaglutide Boom and India’s Expanding Market
Semaglutide, a GLP-1 receptor agonist, has develop into a significant therapeutic advancement in managing Type 2 diabetes and chronic weight management. Drugs like Mounjaro, Wegovy, and Ozempic have seen sales exceed ₹1,000 crore in under a year, signaling a rapidly expanding market. The impending loss of patent protection is expected to further fuel growth, with generics potentially priced 50-60% lower than innovator drugs.
Strategic Partnerships Define the Landscape
Eris and Natco aren’t alone in recognizing the opportunity. Several pharmaceutical companies are forging partnerships to gain a foothold in this competitive market. Recent examples include OneSource Pharma’s collaboration with Hikma for Saudi Arabia, and Ajanta Pharma’s agreement with Biocon for distribution in Asian and African markets. Cipla and Emcure have also secured distribution deals with Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy), respectively.
What Which means for Indian Patients
The entry of generic semaglutide is poised to significantly improve access to this transformative therapy for Indian patients. India’s expanding metabolic care landscape, coupled with a growing diabetic population and increasing awareness of obesity management, creates a substantial demand for GLP-1 therapies. This increased competition is expected to drive down costs, making treatment more affordable.
Eris Lifesciences Chairman and Managing Director, Amit Bakshi, emphasized the company’s commitment to strengthening its diabetes franchise with innovative therapies. The partnership reflects a proactive strategy to participate in the growing GLP-1 opportunity.
Market Reaction and Future Outlook
The announcement of the Eris-Natco partnership triggered positive market response, with Eris Lifesciences shares increasing by 2.68% on Tuesday, closing at ₹1,387.50 on the Bombay Stock Exchange (BSE). Natco Pharma shares also saw gains.
With regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) already secured for Natco, the launch of generic semaglutide is anticipated in March 2026. This timeline positions the companies to capitalize on the immediate post-patent expiry demand.
Frequently Asked Questions
What is semaglutide? Semaglutide is a GLP-1 receptor agonist used in the management of Type 2 diabetes and chronic weight management.
When will generic semaglutide be available in India? Generic semaglutide is expected to launch in India in March 2026.
What are the benefits of generic semaglutide? Generic versions are expected to be priced 50-60% lower than the innovator drugs, increasing affordability and access.
Who are the key players in India’s semaglutide market? Eris Lifesciences, Natco Pharma, Cipla, Emcure, Ajanta Pharma, and Biocon are among the companies actively involved.
What is a GLP-1 receptor agonist? GLP-1 receptor agonists are a class of drugs that help regulate blood sugar levels and promote weight loss.
Did you know? The demand for semaglutide-based drugs has skyrocketed globally, highlighting the growing necessitate for effective weight management solutions.
Pro Tip: Consult with a healthcare professional to determine if semaglutide is the right treatment option for you.
Stay informed about the latest developments in pharmaceutical partnerships and market trends. Explore more articles on our website to gain deeper insights into the evolving healthcare landscape.